Heart Sisters
JUNE 23, 2024
Most patients aren't experienced enough to be competent in handling a scary new diagnosis, but here's how self-reflection can make a difference during recovery.
HCPLive
JUNE 23, 2024
In this episode, hosts are joined by Grazia Aleppo, MD, for a discussion on the use of inhaled insulin following the INHALE-3 trial and relevant updates in diabetes technology at ADA 2024.
Dr. Smith's ECG Blog
JUNE 23, 2024
Written by Willy Frick A man in his 50s was at home with his family when they heard a thud and rushed into the room to find him unconscious with agonal respirations. His daughter immediately started CPR and another family member called EMS. When EMS arrived the patient was in ventricular fibrillation. They shocked him twice before return of spontaneous circulation.
Med Page Today
JUNE 23, 2024
(MedPage Today) -- ORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks.
HCPLive
JUNE 23, 2024
Halis Akturk, MD, offers an overview of the growing prevalence and dangers associated with cannabis use among patients with type 1 diabetes.
Science Daily - Heart Disease
JUNE 23, 2024
Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men.
Med Page Today
JUNE 23, 2024
(MedPage Today) -- ORLANDO -- For type 1 diabetes patients, switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) maintained glycemic control -- for those who used it as intended, the INHALE 3 trial showed.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Med Page Today
JUNE 23, 2024
(MedPage Today) -- ORLANDO -- Putting type 2 diabetes patients on an automated insulin delivery (AID) pump improved glycemic control, the SECURE-T2D pivotal trial showed. Type 2 diabetes patients started on the Omnipod 5 System, currently approved.
HCPLive
JUNE 23, 2024
MOMENTUM trial data shows pemvidutide reduced body weight by 15.6%, with 78.1% fat loss, highlighting the GLP-1/Glucagon receptor agonist's ability to achieve significant weight reduction and minimal muscle loss.
Cardiovascular Diabetology
JUNE 23, 2024
In a translational study involving animal models and human subjects, Lv et al. demonstrate that arachidonic acid (AA) exhibits cardioprotective effects in diabetic myocardial ischemia, suggesting a departure f.
HCPLive
JUNE 23, 2024
An analysis of over 2.5 million patients with type 2 diabetes shows newer GLP-1 RAs are linked to lower HbA1c levels.
Journal of Cardiothoracic Surgery
JUNE 23, 2024
First rib tumors are extremely rare. Its compression of neurovascularity can easily lead to severe complications such as thoracic outlet syndrome, so early surgical resection is crucial. However, there is no s.
HCPLive
JUNE 23, 2024
Use of LX9211 showed significant benefits for diabetic peripheral neuropathic pain in the phase 2 RELIEF-DPN 1 trial.
Journal of Cardiothoracic Surgery
JUNE 23, 2024
Most metastatic lung tumors present as solid nodules on chest computed tomography (CT). In contrast, ground-glass opacity on chest computed tomography usually suggests low-grade malignant lesions such as adeno.
Frontiers in Cardiovascular Medicine
JUNE 23, 2024
BackgroundIschemia with non-obstructive coronary arteries (INOCA) is a major clinical entity that involves potentially 20%–30% of patients with chest pain. INOCA is typically attributed either to coronary microvascular disease and/or vasospasm, but is likely distinct from classical coronary artery disease (CAD).ObjectivesTo gain insights into the etiology of INOCA and CAD, RNA sequencing of whole blood from patients undergoing both stress testing and elective invasive coronary angiography (ICA)
Journal of Cardiothoracic Surgery
JUNE 23, 2024
The prognostic value of cellular retinoic acid-binding protein 2 (CRABP2), in lung cancer patients remains to be uncertained. Therefore, our research attempted to assess the relationship between CRABP2 and sur.
HeartRhythm
JUNE 23, 2024
Tricuspid regurgitation (TR) is a well-known complication after transvenous pacemaker implantation that is less well described for leadless pacemakers (LPs).1 Previous studies have reported discordant data regarding the incidence of significant TR with LP compared to transvenous systems.
Journal of Cardiothoracic Surgery
JUNE 23, 2024
To explore the independent predictors of pathological mediastinal lymph node (pN2) metastasis in clinical stage IA (cIA) pure-solid non-small cell lung cancer (NSCLC) patients, and to find an appropriate metho.
HeartRhythm
JUNE 23, 2024
Early recurrence of atrial tachyarrhythmias (ERAT) within 3 months of thermal ablation for atrial fibrillation (AF) is common and often considered transient. Pulsed field ablation (PFA) is a nonthermal energy source in which ERAT is not well described.
BMH Medical Journal
JUNE 23, 2024
Eosinophilic meningitis (EM) presents a diagnostic challenge due to its varied etiologies, encompassing both infectious and non-infectious causes. Typically, cerebrospinal fluid (CSF) devoid of eosinophils serves as the norm, with their presence indicating a potential underlying condition such as parasitic infections or other systemic disorders.
Journal of Cardiothoracic Surgery
JUNE 23, 2024
Infective endocarditis (IE) is a rare cardiovascular complication in patients with coronavirus disease 2019 (COVID-19).
Cardiovascular Diabetology
JUNE 23, 2024
Diabetic peripheral neuropathy (DPN) is the most prevalent complication of diabetes, and has been demonstrated to be independently associated with cardiovascular events and mortality. This aim of this study wa.
Stroke Journal
JUNE 23, 2024
Stroke, Volume 55, Issue 7 , Page 1729-1729, July 1, 2024.
HeartRhythm
JUNE 23, 2024
Direct oral anticoagulants (DOACs) reduce stroke risk in patients with device-detected atrial fibrillation (DD-AFib) but increase major bleeding risk. The time to benefit (TTB) and time to harm (TTH) are not well quantified.
Stroke Journal
JUNE 23, 2024
Stroke, Volume 55, Issue 7 , Page e189-e190, July 1, 2024.
HeartRhythm
JUNE 23, 2024
Direct oral anticoagulants (DOACs) are the preferred anticoagulant strategy for stroke prevention in patients with atrial fibrillation. Concomitantly, non-dihydropyridine (non-DHP) calcium channel blockers (CCBs) and beta-blockers are commonly utilized for rate control in this cohort. Existing research has shown a potential increase in bleeding risk associated with administering non-DHP CCBs with anticoagulants; however, these findings remain tentative, attributed to variations in study design,
Stroke Journal
JUNE 23, 2024
Stroke, Volume 55, Issue 7 , Page e235-e235, July 1, 2024.
HeartRhythm
JUNE 23, 2024
Catheter ablation has become the most effective rhythm control strategy in treating atrial fibrillation (AF), preventing AF recurrence and delaying its progression to persistent AF better than antiarrhythmic drugs. Furthermore, among patients with heart failure, both reduced and preserved ejection fraction, catheter ablation reduces heart failure hospitalizations and mortality.
Stroke Journal
JUNE 23, 2024
Stroke, Volume 55, Issue 7 , Page e234-e234, July 1, 2024.
The American Journal of Cardiology
JUNE 23, 2024
Publication date: Available online 23 June 2024 Source: The American Journal of Cardiology Author(s): Ebenezer Oni, Ellen Boakye, Gregg S. Pressman, Zeina Dardari, Kunal Jha, Moyses Szklo, Matthew Budoff, Khurram Nasir, Timothy M. Hughes, Michael J.
Stroke Journal
JUNE 23, 2024
Stroke, Volume 55, Issue 7 , Page e232-e232, July 1, 2024.
Stroke Journal
JUNE 23, 2024
Stroke, Volume 55, Issue 7 , Page e231-e231, July 1, 2024.
Expert insights. Personalized for you.
131 
Let's personalize your content